Erythrosine Market

Future Market Insights opines that the erythrosine market is entering a terminal regulatory contraction in its primary market, where the FDA's April 2025 formal delisting of Red No. 3 from US food and drug use, with enforcement deadlines set for January 2027 and January 2028, is compressing the addressable North American market while simultaneously creating a formulator-driven demand surge for validated natural red alternatives that erythrosine producers are ill-positioned to supply.